{"id":1238,"date":"2024-07-01T11:37:11","date_gmt":"2024-07-01T02:37:11","guid":{"rendered":"https:\/\/www.neurosci.med.tohoku.ac.jp\/?p=1238"},"modified":"2024-07-01T11:37:11","modified_gmt":"2024-07-01T02:37:11","slug":"new-publication-front-neurol","status":"publish","type":"post","link":"https:\/\/www.neurosci.med.tohoku.ac.jp\/en\/2024\/07\/01\/new-publication-front-neurol\/","title":{"rendered":"New publication (Front Neurol)"},"content":{"rendered":"\n<p>A study with Kohnan Hospital, Iwate Prefectural Central Hospital, and  Tohoku University Hospital was published in Front Neurol.<br><br>Prophylactic management of cerebral vasospasm with clazosentan in real clinical practice: a single-center retrospective cohort study. Front Neurol 15:1413632, 2024.<br><br>Recent randomized phase 3 trial in Japan demonstrated that clazosentan reduces cerebral vasospasm and improved outcome after subarachnoid hemorrhage (SAH) compared with placebo. However, real-world data comparing clazosentan with conventional standard management such as intravenous fasudil chloride are still lacking.<br>In this study, we compared the efficacy and safety of clazosentan in a group treated with a postoperative management protocol based on clazosentan (n = 81) with a group managed with a conventional protocol (n = 100) after SAH. The results showed that a postoperative management protocol centering on clazosentan was associated with the reduced vasospasm-related symptomatic infarction and improved clinical outcomes compared to the conventional management protocol in Japanese clinical practice. Clazosentan might be a promising treatment option for counteracting cerebral vasospasm after aneurysmal SAH.<\/p>\n\n\n\n<p>This study is a single-center (Konan Hospital) retrospective observational cohort study using data collected from consecutive cases of aneurysmal SAH.<\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A study with Kohnan Hospital, Iwate Prefectural Central Hospital, and Tohoku University Hospital was published in Front Neurol. Prophylactic management of cerebral vasospasm with clazosentan in real clinical practice: a single-center retrospective cohort study. Front Neurol 15:1413632, 2024. Recent randomized phase 3 trial in Japan demonstrated that clazosentan reduces cerebral &hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_locale":"en_US","_original_post":"https:\/\/www.neurosci.med.tohoku.ac.jp\/?p=1238","footnotes":""},"categories":[20],"tags":[],"class_list":["post-1238","post","type-post","status-publish","format-standard","hentry","category-paper","en-US"],"_links":{"self":[{"href":"https:\/\/www.neurosci.med.tohoku.ac.jp\/wp-json\/wp\/v2\/posts\/1238","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.neurosci.med.tohoku.ac.jp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.neurosci.med.tohoku.ac.jp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.neurosci.med.tohoku.ac.jp\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.neurosci.med.tohoku.ac.jp\/wp-json\/wp\/v2\/comments?post=1238"}],"version-history":[{"count":3,"href":"https:\/\/www.neurosci.med.tohoku.ac.jp\/wp-json\/wp\/v2\/posts\/1238\/revisions"}],"predecessor-version":[{"id":1241,"href":"https:\/\/www.neurosci.med.tohoku.ac.jp\/wp-json\/wp\/v2\/posts\/1238\/revisions\/1241"}],"wp:attachment":[{"href":"https:\/\/www.neurosci.med.tohoku.ac.jp\/wp-json\/wp\/v2\/media?parent=1238"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.neurosci.med.tohoku.ac.jp\/wp-json\/wp\/v2\/categories?post=1238"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.neurosci.med.tohoku.ac.jp\/wp-json\/wp\/v2\/tags?post=1238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}